Thermo Scientific Adds Large Molecule Functionality to its Industry-Leading LIMS for Bioanalytical Laboratories
Complete the form below to unlock access to ALL audio articles.
Thermo Fisher Scientific Inc. has announced that its Thermo Scientific Watson LIMS (laboratory information management system) offers enhanced functionality for large molecule bioanalysis in pharmaceutical and contract research organization (CRO) laboratories.
Watson LIMS™ now integrates the data from both small and large molecule research within a single database by facilitating the workflow and extending instrument integration to large molecule bioanalysis.
Watson extends the flexibility of the cutpoint calculations in the immune response module (IRM) and allows samples analyzed with the IRM to be processed through Watson’s incurred sample reanalysis (ISR) functionality.
The company is featuring Watson LIMS within Thermo Scientific booth 1 at the Vancouver Convention Center (Parkview Terrace - Rooms 1, 2 and 3) during ASMS 2012, being held May 20-24.
Historically, most drug development has revolved around small molecule research, requirements for which have been defined at The Crystal City Conference, However, these methods were not always adequate to manage the complexity of large molecule bioanalysis because the research workflow and data analysis is often quite different for large molecules than it is for small molecules.
For pharmaceutical companies with a balanced portfolio and scientists involved in both small and large molecule research, the process of transferring data from one side of the laboratory to the other has been largely a manual process, further complicating the workflow and potentially introducing error.
Additional functionality in Watson LIMS now closes the gap between small and large molecule research and brings connectivity to the bioanalytical laboratory.
“With the extended functionality of Watson now encompassing large molecule research as well as small, the bioanalytical laboratory has the industry-leading LIMS managing two previously separate parts of the drug development process,” said Dave Champagne, vice president and general manager of Informatics at Thermo Fisher.
Champagne continued, “This allows scientists in the field to combine activities and processes, thereby saving time and precious resources and increasing the speed at which new compounds are introduced to the market. With the ongoing advances in biomarker research, Watson is perfectly aligned to add value to some of the next decade’s most important scientific efforts.”
Further illustrating Thermo Fisher’s commitment to its CONNECTS initiative, introduced in 2009, Watson facilitates the integration of the bioanalytical lab by the alignment of workflows, connectivity of instrumentation and consolidation of databases, thereby allowing scientists to more easily and accurately manage their data across the laboratory and have more control of the information they generate.
Thermo Scientific Watson LIMS, the leading bioanalytical laboratory information management system relied upon by 18 of the top 20 pharmaceutical companies and CROs worldwide, is designed to bring critical time and cost savings to pharmaceutical companies and CROs involved in drug metabolism and pharmacokinetic (DMPK) studies for drug discovery and development.
The purpose-built functionality of Watson delivers improved efficiencies and reduced validation time for pharmaceutical companies and CROs, contributing to time and cost savings.
Pharmaceutical companies and CROs worldwide that standardize on Watson LIMS can count on secure data transmissions, regulatory compliance, reliable audit trails and improved time to market.
